VOOZH about

URL: https://pubmed.ncbi.nlm.nih.gov/41096176/

⇱ The Way of SARS-CoV-2 Pneumonia-An Early-Pandemic Review of the Key Manifestations and Severity - PubMed


Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
πŸ‘ Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

πŸ‘ Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Abstract

The disease COVID-19, which has befallen mankind in recent years, was a challenge that we had not faced for centuries. The first registered patient case was in China. This review is performed by the inspection of a large body of worldwide investigations conducted in the peak period of the disease's progress. The disease is spread by airborne droplets and develops mainly with fever, cough, sputum, and shortness of breath. Laboratory tests show leukopenia, lymphopenia, a decrease in the levels of sodium, potassium, and calcium, and an increase in the levels of CRP, LDH, and D-dimer. Radiological changes in most cases are bilateral and of the "ground glass" type in the lower parts of the lungs. The most severe complication of COVID-19 pneumonia is ARDS. The risk groups are people with chronic lung diseases, the elderly, and those who are overweight. This article analyzes and summarizes the main characteristics of SARS-CoV-2 pneumonia in order to better understand and apply better clinical management of this condition.

Keywords: COVID-19; RNA virus; infection; pneumonia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. WHO Report 2020, 4 Coronavirus Disease 2019 (COVID-19) Situation Report 2020. [(accessed on 18 August 2025)]. Available online: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mis....
    1. Dhama K., Patel S.K., Pathak M., Yatoo M.I., Tiwari R., Malik Y.S., Singh R., Sah R., Rabaan A.A., Bonilla-Aldana D.K., et al. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med. Infect. Dis. 2020;37:101755. doi: 10.1016/j.tmaid.2020.101755. - DOI - PMC - PubMed
    1. Kamps B.S., Hofmann C. COVID Reference. 6th ed. Steinhauser Verlag; Stuttgart, Germany: 2021. p. 3.
    1. Sun L., Li P., Ju X., Rao J., Huang W., Ren L., Zhang S., Xiong T., Xu K., Zhou X., et al. In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs. Cell. 2021;184:1865–1883.e20. doi: 10.1016/j.cell.2021.02.008. - DOI - PMC - PubMed
    1. Zhang H., Penninger J.M., Li Y., Zhong N., Slutsky A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–590. doi: 10.1007/s00134-020-05985-9. - DOI - PMC - PubMed

LinkOut - more resources

Cite

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.